ATOSSA Genetics positioniert sich perfekt um zu alten und neuen Höhen durchzustarten (Seite 4)
eröffnet am 18.09.13 15:23:55 von
neuester Beitrag 18.02.24 13:16:37 von
neuester Beitrag 18.02.24 13:16:37 von
Beiträge: 785
ID: 1.186.261
ID: 1.186.261
Aufrufe heute: 0
Gesamt: 232.984
Gesamt: 232.984
Aktive User: 0
ISIN: US04962H5063 · WKN: A2JJ99 · Symbol: ATOS
1,5000
USD
+0,67 %
+0,0100 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
15.04.24 · globenewswire  |
11.04.24 · globenewswire |
09.04.24 · globenewswire |
01.04.24 · globenewswire |
20.03.24 · wO Chartvergleich |
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 41,51 | +38,37 | |
| 0,5750 | +26,18 | |
| 1,5000 | +13,64 | |
| 5,3000 | +12,77 | |
| 6,2500 | +10,62 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,4240 | -12,37 | |
| 0,5925 | -15,36 | |
| 1,5500 | -30,49 | |
| 2,1500 | -36,79 | |
| 73,27 | -49,61 |
Beitrag zu dieser Diskussion schreiben
Feedback
Fallen heute die 7 Euro?
Man orientiert sich auf Tradegate halt an der Amibörse:
Antwort auf Beitrag Nr.: 68.592.055 von skynetwork am 23.06.21 15:45:00
Servus. Läuft doch sehr gut in meinen Augen.
https://www.cnbc.com/quotes/ATOS?qsearchterm=atos
Zitat von skynetwork: ... sind bloß mittlerweile auch schon wieder die professionellen Hedge-Shorter drauf aufmerksam geworden und dumpen das Ding nun wieder runter.... sehr ätzend.
Servus. Läuft doch sehr gut in meinen Augen.
https://www.cnbc.com/quotes/ATOS?qsearchterm=atos
... sind bloß mittlerweile auch schon wieder die professionellen Hedge-Shorter drauf aufmerksam geworden und dumpen das Ding nun wieder runter.... sehr ätzend.
Update
Hello folks. This is part 2 of my ATOS DD posted in May here. Go read that post for background on this play and why I’m confident in it. Pretty much everything is on track: as predicted, ATOS has been confirmed to be added to the R2K, the company gave an update on Endoxifen, and the open interest in calls fueled some MM buying.
Since the time of writing part 1 DD, ATOS has climbed from $2.9 to a close of $5.35 - an 85% increase. If you’d followed my suggestions (buying on dips, not going too far OTM on calls, etc.) you should be doing pretty well.
In this DD I will cover the major catalysts remaining and how I expect them to play out. I’ll also explain why I believe this is more interesting than any other R2K inclusion play out there. Finally, I’ll provide some suggestions for how to not lose your shirt and secure profits while maximising your upside.
TL
R; ATOS is still on track to rocket. While some of the gains have been achieved already, the major gains are yet to come. I expect that over 20M shares will have to be bought indiscriminately between now and the end of July. Given that the total outstanding shares are 120M with about 12M held by institutions, this is a large position of the float for a pretty illiquid stock.
There is less than a week left before the massive share buying begins!
The rest of this DD will cover
4 upcoming catalysts (R2K buying, MM buying, Short buying, and fundamentals)
Suggestions for how to invest
Thoughts on exit strategies
Disclaimer: I am long ATOS. I am sharing research and some thoughts on how I am thinking about trading. Trade your own way, do your own DD. I have no professional financial training and am not a financial advisor.
Catalyst 1: R2K buying (June through July)
ATOS has been confirmed as added to the R2K. This means that index funds, mutual funds, pension funds, index futures will all start to add ATOS this week in huge amounts. Currently, ATOS’s institutional holdings sit at about 10% which is incredibly low for an equity in the R2K. Peers have holdings in the 30-50% range, so at some point I expect 20-40% of ATOS shares to be bought by institutions.
However, in particular on June 25th, primarily at close at the end of the trading day, passive funds will buy somewhere between 10M and 15M shares. The actual amount depends on the relative market cap of ATOS to the total market cap of R2K.
A few weeks ago, some folks obtained this data from a large bank’s trading desk that estimated 11.5M shares of ATOS to be bought based on data since the end of May.
Post image
However, ATOS is up 66% while IWM (one Russell 2000 ETF) is down 1.5% since the end of May, so there is good reason to believe the number above could be under-estimating by 50% or more. In other words, there’s a chance that passive funds alone have to buy 20M shares this coming Friday June 25. Also, the higher ATOS goes this week before Friday, the more shares that will have to be bought on Friday.
Post image
Post image
In addition to passive funds, there are many actively managed funds that are benchmarked to the R2K. If they want to reduce their tracking risk vs. the benchmark, they will likely buy some ATOS as well, though it’s impossible to predict when and how much they will buy. It will be more than 0.
Catalyst 2: Call Options & MM buying (July OpEx)
If 20M shares bought by passive funds on Friday is a torch, the call OI on ATOS is a fucking haystack.
Since my last post, call open interest has increased 20% from 395K calls to 499K calls! In addition, more than 50% of all calls are for July.
Post image
Look, I’ve seen a ton of posts on people betting on R2K inclusion. To give you a sense of how fucking special ATOS is, u/Swol_Braham helped me analyze all 255 stocks being added to the R2K. We pulled the official pdf list of all 2021 additions, converted it to a spreadsheet, then pulled in data on total shares outstanding and total call OI for all 255 stocks.
We then ranked all the inclusions by the total call OI / total shares outstanding - and ATOS is #2 on the entire list. Cool, not bad. However, as I mentioned before, the closer the expiry the more the share buying by MMs, so we looked at the July expirations for the top 10, and holy fucking shit: ATOS has more than 10X the relative July Call OI of other stocks being added to the R2K.
Post image
ATOS has the highest ratio of July call OI vs shares outstanding out of all 250+ stocks being added to R2K
This is un-fucking-believable. ATOS July calls represent a potential buy of 23% of the underlying shares. Here’s the sheet if you want to verify the data yourself.
I cannot overemphasize the potential for a massive, massive gamma squeeze event here if things go well. And remember, I wrote a lot of DD on a famous video gamer retail stock and I still never saw anything like this.
And you know what? Call OI is just increasing. Here is a chart of ATOS call OI over the last year and price. Something like 14% of all July calls were just bought last week.
Post image
If you’re in ATOS you should strongly think twice about selling before July Opex. I’ve never seen a setup this amazing for a gamma squeeze before.
Catalyst 3: Potential short covering
I really don’t know why in 2021 funds are taking these huge short positions anymore, but ATOS is a stock with heavy short interest. To be clear, this is not primarily a short squeeze play but there is significant interest for a short squeeze.
Shorts have actually added to their positions since my last DD, increasing total short shares to 13M shares short with 100% utilization of borrowed shares. Based on some back-of-the-napkin calculations, shorts likely have entered at an average price of $2.8 - $3.2 a share, so are very underwater now.
Post image
Post image
Fintel rates ATOS as a short squeeze candidate, ranking it #38 out of over 10,000 equities it scores.
Post image
Catalyst 4: Fundamentals (July - Sept)
Endoxifen Update
ATOS’s main drug in development is Endoxifen, which is targeted for use with breast cancer prevention and treatment. Breast cancer is one of the most common cancers in the US, the most common cancer in women, and the 2nd leading cause of cancer-driven deaths in women.
“The American Cancer Society (ACS) estimates that in 2021, 281,550 women will be diagnosed with breast cancer in the U.S. and 43,600 will die.” (source).
Endoxifen contains some of the same components of Tamoxifen, which is a generic chemotherapy drug that is currently the gold standard for breast cancer patients. Endoxifen is more effective than the generic as Tamoxifen doesn’t work with a portion of patients with a certain genotype.
ATOS released an update about its phase 2 trials in early June (summary), after which the stock dropped quite a bit. For what it’s worth, I believe the negative price move was largely initiated by heavy shorting to make the market think the news was bad (see shorting increase above), so I added a whole bunch of shares on the drop.
The gist of the update: "Based on these favorable results, we are taking a number of steps to quickly advance our development of Endoxifen.” Given the end of a successful phase 2, and the fact that Endoxifen is a more effective drug than a generic that is the most common treatment for the most common cancer in women AND if you follow M&A activity, you’ll find that buyouts are most common after a successful phase 2, there’s an interesting chance for another catalyst here.
Post image
There were allusions in the recent call towards more updates coming in Q3 (i.e. July onwards) and there have since already been some releases indicating further progress is being made, with some unverifiable twitter folks suggesting more positive news coming the week of the 28th.
I’m not putting a lot of faith in fundamental updates in the short term - however, if ATOS were to release significant positive news this week or next, it could drive further buying and add to the impact of the other catalysts above.
Major Risks
Some of the major risks since the last post have been removed (i.e. would ATOS actually be added to R2K, would Endoxifen results show failure). However, there are a few major risks remaining, and you should make sure you’re aware before investing/speculating here:
Short sellers: ATOS is a heavily shorted stock. On the one hand, this means that there is a chance of a short squeeze. On the other hand, it means that hedge funds with money are interested in pushing the value of the stock down. I do not assume they are dumb, and they should be able to see what’s coming. They may have something planned for inclusion and post-inclusion.
Inclusion sellers: There is no way of knowing how many people have already bought shares, and how much they have bought, for the purposes of the inclusion play. If there are more sellers than buyers on the 25th (i.e. they don’t pay attention to the call OI in July) there may not be enough of a strong lift to kick off a gamma squeeze.
Gamma unwind: Most hedging for options occurs the week of expiration (July 16), which is a couple of weeks after the inclusion buys occurring on the 25th. If ATOS goes red and stays red the week after inclusion, then MMs will start to unwind the shares hedged for the 270K call options in July.
Price is higher than before: In my first post I described ATOS as a highly asymmetrical play, with a cash value of $1.XX a share and a market price of only 2X the cash value. Since then, the price of ATOS has grown to $5.35 a share, so while I strongly still believe in upside it’s a bit less asymmetrical now (i.e. more downside risk).
How to Be Smart and Not Lose All Your Money
I’m going to re-share a trimmed version of this guide from part 1 as it’s heavily relevant here as well. Here’s some things to be careful about.
I don’t recommend covered calls for July: The IV is high. No one knows exactly how many shares will be bought from now until the end of July, but it will be in the tens of millions. On an illiquid stock like ATOS, the market impact (i.e. impact to price) of this type of buying activity could be insane. It is possible that every strike for July goes ITM at some point. I am not shorting any calls for July.
Shares and July calls are my choice of vehicle. Get calls if you’re ok for paying the high premium for leverage and you don’t have enough capital for the exposure you want via shares. Shares are the safest and most liquid, as you’ll lose with calls on the bid-ask spread during buying and selling and also paying the high IV.
Save dry powder to buy on dips. Dips manufactured by shorts are buying opportunities. Take advantage of folks with paper hands to capture shares at low points. ATOS has incredible daily volatility. Set a low limit buy and just wait for the order to fill. Have patience when buying.
Don’t bet more than you can afford to lose. ATOS dropped 40% in a few days after hitting like $6.5 after the initial R2K confirmation (and has since recovered a bit). Over-extending yourself means you’re more likely to sell on dips and lose the upside. Consider spreading your purchases out.
Don’t sell on dips. You’re only helping the shorts. If you need to sell to take profits, sell when it’s heading up. Sell high, not low, retards.
Don’t buy calls on rips. With everyone expecting a squeeze at any moment option premiums that are already high rocket to insane levels in minutes. You’re absolutely fucked if you buy calls on rips, even if you’re right.
Be careful about buying on margin. Brokers are rapidly increasing margins. If you bought on margin with 2:1 leverage, and the stock went up 100%, you’d be in margin call even without a margin change. If the broker moves margin against you, you’ll get to margin call faster. Someone messaged me asking for help because they bought calls on margin, and they bought the calls on a rip. Don’t do this.
Watch out for stop loss hunts. It’s common practice for shorts to hunt for stop losses for cheap shares. DON’T SET STOP LOSSES.
HOLD. There is so much upside in ATOS, that it doesn’t matter what price you buy now if you have patience and wait for inclusion. Don’t give up your shares for cheap.
How to Protect Your Gains while Maintaining Upside Exposure and Helping a Gamma Squeeze
If you’ve followed my part 1, you should have a good amount of gains from your buy-in already. If you’d like to play the gamma squeeze but want to secure some profits, consider buying puts as insurance for your shares before next week.
For example, if ATOS more than doubles to $11 this week as this brodir predicts, you could buy July 10p. Let’s say for example the July 10p cost $1, and you buy 1 10p for every 100 shares you own, and let your shares ride. That means in the worst case scenario, you get $9 for every share you own on July 16. If ATOS is above $9/share, you can sell your shares at market price or hold (up to you). Your downside is capped and your upside is uncapped.
This is much better than selling covered calls, which cap your upside but don’t cap your downside.
This is also better imo than “taking profits” selling part of your shares, as that means the rest of your shares are less likely to do as well as by selling shares you are reducing pressure on the gamma squeeze.
When you buy a put, a MM (in theory) hedges your put by initially selling shares according to the delta of a put. So for example if you buy a put with delta .3, the MM is selling 30 shares for every put you buy. However, if ATOS goes up since you and others like you are still holding your shares while active funds and MMs have to buy to hedge july calls, the delta (and value) of your put will go to zero, which means MMs will re-buy the shares they shorted when you bought your put. So, not only did you protect your downside, but you force MMs to buy shares as the price goes up - which actually helps the chances of a gamma squeeze (compared to if you had just sold your shares or sold a covered call).
Summary
The next few weeks have many significant upside catalysts for ATOS. Passive buying begins in earnest this week at the EOD on June 25, but there is additional buying throughout July expected.
ATOS is uniquely positioned to benefit from a gamma squeeze from forced MM buying and passive fund buying due to the Russell 2k reconstitution. I have literally never seen a better setup before, and that’s including a certain famous meme stock.
Call open interest is huge and rising.
I am adding to my positions on any dips this week.
Quelle: https://www.reddit.com/r/AtossaTherapeutics/comments/o662q2/…
Hello folks. This is part 2 of my ATOS DD posted in May here. Go read that post for background on this play and why I’m confident in it. Pretty much everything is on track: as predicted, ATOS has been confirmed to be added to the R2K, the company gave an update on Endoxifen, and the open interest in calls fueled some MM buying.
Since the time of writing part 1 DD, ATOS has climbed from $2.9 to a close of $5.35 - an 85% increase. If you’d followed my suggestions (buying on dips, not going too far OTM on calls, etc.) you should be doing pretty well.
In this DD I will cover the major catalysts remaining and how I expect them to play out. I’ll also explain why I believe this is more interesting than any other R2K inclusion play out there. Finally, I’ll provide some suggestions for how to not lose your shirt and secure profits while maximising your upside.
TL
R; ATOS is still on track to rocket. While some of the gains have been achieved already, the major gains are yet to come. I expect that over 20M shares will have to be bought indiscriminately between now and the end of July. Given that the total outstanding shares are 120M with about 12M held by institutions, this is a large position of the float for a pretty illiquid stock.There is less than a week left before the massive share buying begins!
The rest of this DD will cover
4 upcoming catalysts (R2K buying, MM buying, Short buying, and fundamentals)
Suggestions for how to invest
Thoughts on exit strategies
Disclaimer: I am long ATOS. I am sharing research and some thoughts on how I am thinking about trading. Trade your own way, do your own DD. I have no professional financial training and am not a financial advisor.
Catalyst 1: R2K buying (June through July)
ATOS has been confirmed as added to the R2K. This means that index funds, mutual funds, pension funds, index futures will all start to add ATOS this week in huge amounts. Currently, ATOS’s institutional holdings sit at about 10% which is incredibly low for an equity in the R2K. Peers have holdings in the 30-50% range, so at some point I expect 20-40% of ATOS shares to be bought by institutions.
However, in particular on June 25th, primarily at close at the end of the trading day, passive funds will buy somewhere between 10M and 15M shares. The actual amount depends on the relative market cap of ATOS to the total market cap of R2K.
A few weeks ago, some folks obtained this data from a large bank’s trading desk that estimated 11.5M shares of ATOS to be bought based on data since the end of May.
Post image
However, ATOS is up 66% while IWM (one Russell 2000 ETF) is down 1.5% since the end of May, so there is good reason to believe the number above could be under-estimating by 50% or more. In other words, there’s a chance that passive funds alone have to buy 20M shares this coming Friday June 25. Also, the higher ATOS goes this week before Friday, the more shares that will have to be bought on Friday.
Post image
Post image
In addition to passive funds, there are many actively managed funds that are benchmarked to the R2K. If they want to reduce their tracking risk vs. the benchmark, they will likely buy some ATOS as well, though it’s impossible to predict when and how much they will buy. It will be more than 0.
Catalyst 2: Call Options & MM buying (July OpEx)
If 20M shares bought by passive funds on Friday is a torch, the call OI on ATOS is a fucking haystack.
Since my last post, call open interest has increased 20% from 395K calls to 499K calls! In addition, more than 50% of all calls are for July.
Post image
Look, I’ve seen a ton of posts on people betting on R2K inclusion. To give you a sense of how fucking special ATOS is, u/Swol_Braham helped me analyze all 255 stocks being added to the R2K. We pulled the official pdf list of all 2021 additions, converted it to a spreadsheet, then pulled in data on total shares outstanding and total call OI for all 255 stocks.
We then ranked all the inclusions by the total call OI / total shares outstanding - and ATOS is #2 on the entire list. Cool, not bad. However, as I mentioned before, the closer the expiry the more the share buying by MMs, so we looked at the July expirations for the top 10, and holy fucking shit: ATOS has more than 10X the relative July Call OI of other stocks being added to the R2K.
Post image
ATOS has the highest ratio of July call OI vs shares outstanding out of all 250+ stocks being added to R2K
This is un-fucking-believable. ATOS July calls represent a potential buy of 23% of the underlying shares. Here’s the sheet if you want to verify the data yourself.
I cannot overemphasize the potential for a massive, massive gamma squeeze event here if things go well. And remember, I wrote a lot of DD on a famous video gamer retail stock and I still never saw anything like this.
And you know what? Call OI is just increasing. Here is a chart of ATOS call OI over the last year and price. Something like 14% of all July calls were just bought last week.
Post image
If you’re in ATOS you should strongly think twice about selling before July Opex. I’ve never seen a setup this amazing for a gamma squeeze before.
Catalyst 3: Potential short covering
I really don’t know why in 2021 funds are taking these huge short positions anymore, but ATOS is a stock with heavy short interest. To be clear, this is not primarily a short squeeze play but there is significant interest for a short squeeze.
Shorts have actually added to their positions since my last DD, increasing total short shares to 13M shares short with 100% utilization of borrowed shares. Based on some back-of-the-napkin calculations, shorts likely have entered at an average price of $2.8 - $3.2 a share, so are very underwater now.
Post image
Post image
Fintel rates ATOS as a short squeeze candidate, ranking it #38 out of over 10,000 equities it scores.
Post image
Catalyst 4: Fundamentals (July - Sept)
Endoxifen Update
ATOS’s main drug in development is Endoxifen, which is targeted for use with breast cancer prevention and treatment. Breast cancer is one of the most common cancers in the US, the most common cancer in women, and the 2nd leading cause of cancer-driven deaths in women.
“The American Cancer Society (ACS) estimates that in 2021, 281,550 women will be diagnosed with breast cancer in the U.S. and 43,600 will die.” (source).
Endoxifen contains some of the same components of Tamoxifen, which is a generic chemotherapy drug that is currently the gold standard for breast cancer patients. Endoxifen is more effective than the generic as Tamoxifen doesn’t work with a portion of patients with a certain genotype.
ATOS released an update about its phase 2 trials in early June (summary), after which the stock dropped quite a bit. For what it’s worth, I believe the negative price move was largely initiated by heavy shorting to make the market think the news was bad (see shorting increase above), so I added a whole bunch of shares on the drop.
The gist of the update: "Based on these favorable results, we are taking a number of steps to quickly advance our development of Endoxifen.” Given the end of a successful phase 2, and the fact that Endoxifen is a more effective drug than a generic that is the most common treatment for the most common cancer in women AND if you follow M&A activity, you’ll find that buyouts are most common after a successful phase 2, there’s an interesting chance for another catalyst here.
Post image
There were allusions in the recent call towards more updates coming in Q3 (i.e. July onwards) and there have since already been some releases indicating further progress is being made, with some unverifiable twitter folks suggesting more positive news coming the week of the 28th.
I’m not putting a lot of faith in fundamental updates in the short term - however, if ATOS were to release significant positive news this week or next, it could drive further buying and add to the impact of the other catalysts above.
Major Risks
Some of the major risks since the last post have been removed (i.e. would ATOS actually be added to R2K, would Endoxifen results show failure). However, there are a few major risks remaining, and you should make sure you’re aware before investing/speculating here:
Short sellers: ATOS is a heavily shorted stock. On the one hand, this means that there is a chance of a short squeeze. On the other hand, it means that hedge funds with money are interested in pushing the value of the stock down. I do not assume they are dumb, and they should be able to see what’s coming. They may have something planned for inclusion and post-inclusion.
Inclusion sellers: There is no way of knowing how many people have already bought shares, and how much they have bought, for the purposes of the inclusion play. If there are more sellers than buyers on the 25th (i.e. they don’t pay attention to the call OI in July) there may not be enough of a strong lift to kick off a gamma squeeze.
Gamma unwind: Most hedging for options occurs the week of expiration (July 16), which is a couple of weeks after the inclusion buys occurring on the 25th. If ATOS goes red and stays red the week after inclusion, then MMs will start to unwind the shares hedged for the 270K call options in July.
Price is higher than before: In my first post I described ATOS as a highly asymmetrical play, with a cash value of $1.XX a share and a market price of only 2X the cash value. Since then, the price of ATOS has grown to $5.35 a share, so while I strongly still believe in upside it’s a bit less asymmetrical now (i.e. more downside risk).
How to Be Smart and Not Lose All Your Money
I’m going to re-share a trimmed version of this guide from part 1 as it’s heavily relevant here as well. Here’s some things to be careful about.
I don’t recommend covered calls for July: The IV is high. No one knows exactly how many shares will be bought from now until the end of July, but it will be in the tens of millions. On an illiquid stock like ATOS, the market impact (i.e. impact to price) of this type of buying activity could be insane. It is possible that every strike for July goes ITM at some point. I am not shorting any calls for July.
Shares and July calls are my choice of vehicle. Get calls if you’re ok for paying the high premium for leverage and you don’t have enough capital for the exposure you want via shares. Shares are the safest and most liquid, as you’ll lose with calls on the bid-ask spread during buying and selling and also paying the high IV.
Save dry powder to buy on dips. Dips manufactured by shorts are buying opportunities. Take advantage of folks with paper hands to capture shares at low points. ATOS has incredible daily volatility. Set a low limit buy and just wait for the order to fill. Have patience when buying.
Don’t bet more than you can afford to lose. ATOS dropped 40% in a few days after hitting like $6.5 after the initial R2K confirmation (and has since recovered a bit). Over-extending yourself means you’re more likely to sell on dips and lose the upside. Consider spreading your purchases out.
Don’t sell on dips. You’re only helping the shorts. If you need to sell to take profits, sell when it’s heading up. Sell high, not low, retards.
Don’t buy calls on rips. With everyone expecting a squeeze at any moment option premiums that are already high rocket to insane levels in minutes. You’re absolutely fucked if you buy calls on rips, even if you’re right.
Be careful about buying on margin. Brokers are rapidly increasing margins. If you bought on margin with 2:1 leverage, and the stock went up 100%, you’d be in margin call even without a margin change. If the broker moves margin against you, you’ll get to margin call faster. Someone messaged me asking for help because they bought calls on margin, and they bought the calls on a rip. Don’t do this.
Watch out for stop loss hunts. It’s common practice for shorts to hunt for stop losses for cheap shares. DON’T SET STOP LOSSES.
HOLD. There is so much upside in ATOS, that it doesn’t matter what price you buy now if you have patience and wait for inclusion. Don’t give up your shares for cheap.
How to Protect Your Gains while Maintaining Upside Exposure and Helping a Gamma Squeeze
If you’ve followed my part 1, you should have a good amount of gains from your buy-in already. If you’d like to play the gamma squeeze but want to secure some profits, consider buying puts as insurance for your shares before next week.
For example, if ATOS more than doubles to $11 this week as this brodir predicts, you could buy July 10p. Let’s say for example the July 10p cost $1, and you buy 1 10p for every 100 shares you own, and let your shares ride. That means in the worst case scenario, you get $9 for every share you own on July 16. If ATOS is above $9/share, you can sell your shares at market price or hold (up to you). Your downside is capped and your upside is uncapped.
This is much better than selling covered calls, which cap your upside but don’t cap your downside.
This is also better imo than “taking profits” selling part of your shares, as that means the rest of your shares are less likely to do as well as by selling shares you are reducing pressure on the gamma squeeze.
When you buy a put, a MM (in theory) hedges your put by initially selling shares according to the delta of a put. So for example if you buy a put with delta .3, the MM is selling 30 shares for every put you buy. However, if ATOS goes up since you and others like you are still holding your shares while active funds and MMs have to buy to hedge july calls, the delta (and value) of your put will go to zero, which means MMs will re-buy the shares they shorted when you bought your put. So, not only did you protect your downside, but you force MMs to buy shares as the price goes up - which actually helps the chances of a gamma squeeze (compared to if you had just sold your shares or sold a covered call).
Summary
The next few weeks have many significant upside catalysts for ATOS. Passive buying begins in earnest this week at the EOD on June 25, but there is additional buying throughout July expected.
ATOS is uniquely positioned to benefit from a gamma squeeze from forced MM buying and passive fund buying due to the Russell 2k reconstitution. I have literally never seen a better setup before, and that’s including a certain famous meme stock.
Call open interest is huge and rising.
I am adding to my positions on any dips this week.
Quelle: https://www.reddit.com/r/AtossaTherapeutics/comments/o662q2/…
Trading Spotlight
Antwort auf Beitrag Nr.: 68.460.113 von Theta87 am 09.06.21 20:47:12Jetzt kann man in MRKR einsteigen auch Krebs Therapien (T-cell), vorallem Brustkreps.
Ich denke, dass war eine Mischung aus "Sell the News" und eine charttechnische Reaktion. Der RSI war überkauft, wir hatten 2 Gaps nach oben im 4 Stunden Chart und sind gestern und vorgestern an der 161er Fibonnaci-Erweiterung abgeprallt. Da kommt ein erwartbares Ereignis recht. Außerdem war die Marktkapitalisierung sehr hoch, wenn man bspw. mit GLSI, die auch eine Brustkrebsstudie in P2 erfolgreich beendet haben, vergleicht (auch wenn die Therapien natürlich nicht vergleichbar sind)
Jetzt sind die beiden Gaps geschlossen und das 61er Retracement hat als Unterstützung gehalten. Das ist vorerstmal gut. Die Indikatoren können sich erholen. Ich bin ja kein Chartexperte und habe erst vor kurzem angefangen mich mit Elliott-Wellen zu beschäftigen, aber meiner Meinung sind wir jetzt auch in der 4. Welle, die ja korrektiv ist. Daher kann es auch noch tiefer gehen. Die 5. Welle wird das bisherige dann aber toppen. Die Frage ist halt nur: wann?
Dass man hier Geduld mitbringen muss, ist bei Krebs in P2 klar. Die P3 wird noch ne Weile dauern, selbst wenn es eine Interim gibt und diese vorzeitig die Studie beendet. Geld ist ja erstmal genug da. Man muss halt jetzt entscheiden, ob man long ist oder doch nur traded. Bei letzterem wäre ich jetzt vorsichtig. Bei ersterem weiß man eh, dass das hier noch ein langer Weg ist. Daher hatte ich gestern auch einen Teil verkauft und der Rest bleibt stehen. Bin hier allerdings schon länger dabei und kann dem Treiben auch relaxter zusehen.
Jetzt sind die beiden Gaps geschlossen und das 61er Retracement hat als Unterstützung gehalten. Das ist vorerstmal gut. Die Indikatoren können sich erholen. Ich bin ja kein Chartexperte und habe erst vor kurzem angefangen mich mit Elliott-Wellen zu beschäftigen, aber meiner Meinung sind wir jetzt auch in der 4. Welle, die ja korrektiv ist. Daher kann es auch noch tiefer gehen. Die 5. Welle wird das bisherige dann aber toppen. Die Frage ist halt nur: wann?
Dass man hier Geduld mitbringen muss, ist bei Krebs in P2 klar. Die P3 wird noch ne Weile dauern, selbst wenn es eine Interim gibt und diese vorzeitig die Studie beendet. Geld ist ja erstmal genug da. Man muss halt jetzt entscheiden, ob man long ist oder doch nur traded. Bei letzterem wäre ich jetzt vorsichtig. Bei ersterem weiß man eh, dass das hier noch ein langer Weg ist. Daher hatte ich gestern auch einen Teil verkauft und der Rest bleibt stehen. Bin hier allerdings schon länger dabei und kann dem Treiben auch relaxter zusehen.
Antwort auf Beitrag Nr.: 68.457.248 von zzman31 am 09.06.21 17:34:17Ich warte erstmal ab
Ich vermute dass viele SLer rausgekickt worden! Wollte schon verkaufen. Aber beruhigt sich gerade etwas. Für mich sind das top Nachrichten.
Antwort auf Beitrag Nr.: 68.457.137 von zzman31 am 09.06.21 17:24:56Verstehe das auch nicht
Durchsuchen
20.03.24 · wO Chartvergleich · Avista |